The identification of non-neuromuscular complications of severe SMA, including disorders of the heart and cardiovascular system, may help to elucidate pathogenic pathways and are furthermore of increasing clinical importance since therapies that aim to attenuate or reverse SMN deficiency may be introduced soon. Here, SMN1 is linked to proximal spinal muscular atrophy.